The novel HLA-B*55:130 allele, identified by Sanger dideoxy nucleotide sequencing in a Chinese individual.

HLA-B*55:130 differs from HLA-B*55:35 by two nucleotides in exon 2.

[Docetaxel induces apoptosis and influences the expression of P-gp, BCL-2 and BAX protein in HL-60/ADR cells].

This study was aimed to investigate the effect of Docetaxel on drug-resistant leukemia cell line HL-60/ADR and its influence on expression of P-pg, BCL-2 and BAX proteins so as to provide a new strategy and theoretical basis for clinical solution of leukemia drug-resistance. The morphological changes of HL-60/ADR were observed by light and transmission electron microscopes; the cell apoptosis was detected by flow cytometry with Annexin V FITC/PI double labeling; the expressions of P-gp, BCL-2 and BAX were determined by immunohistochemical technique and computer image analysis system. The results showed that the HL-60/ADR cells treated with Docetaxel displayed typical apoptotic morphological changes; the Docetaxel significantly inhibited the growth of HL-60/ADR cells in concentration-and time-dependent manners (r=0.853, r=0.989) and induced the apoptosis of HL-60/ADR cells, but apoptosis rate did not showed the increase trend along with concentration change of drug. The HL-60/ADR cells highly expressed P-gp, there were no significant differences between each groups; the expression of BCL-2 and BAX in HL-60/ADR cells decreased and increased respectively. It is concluded that the Docetaxel induces apoptosis of HL-60/ADR cells, decreases the expression of BCL-2 protein and increases the expression of BAX protein.